Valoctocogene Roxaparvovec
Author: Daniel Chancellor
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Valoctocogene roxaparvovec (BioMarin), also known as valrox, is an adeno-associated virus-mediated gene therapy that delivers human B domain-deleted coagulation factor VIII (fVIII) to patients with hemophilia A. The gene therapy is being developed by BioMarin, which initiated its pivotal Phase III program in December 2017. Valoctocogene roxaparvovec has been granted expedited review designations in both the US and EU, and represents the most advanced gene therapy for any type of hemophilia currently in the pipeline.
Data from Phase II showed a strong reduction in the number of bleeding episodes, albeit with a wide range of fVIII expression levels. The wide variability between patients may allow for spontaneous bleeding episodes in those with lower fVIII expression, while extremely high levels can result in thromboembolic events. The challenge for BioMarin in Phase III will be to create a predictable and stable response to treatment, identifying the correct dose for each patient.
TABLE OF CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 valoctocogene roxaparvovec : Hemophilia
LIST OF FIGURES
9 Figure 1: Valoctocogene roxaparvovec for hemophilia – SWOT analysis
LIST OF TABLES
6 Table 1: Valoctocogene roxaparvovec drug profile
7 Table 2: Valoctocogene roxaparvovec Phase III trials in hemophilia
9 Table 3: Valoctocogene roxaparvovec Phase II data in hemophilia
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Hemlibra 
Sign up to the